Open access · US-GOV
via ClinicalTrials.gov Clinical trial
An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX102-C01 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
Authors not listed
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 2021
Abstract
The goal of this study is to evaluate the safety and efficacy of LX102-C01 treatment of nAMD. This study will enroll subjects aged ≥ 50 years old to receive a single unilateral intravitreal (IVT) injection of LX102-C01 to evaluate its safety and efficacy.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-09 MST
Cite this
APA
Anonymous. (2021). An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX102-C01 in Patients With Neovascular Age-Related Macular Degeneration (nAMD). <em>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</em>. https://clinicaltrials.gov/study/NCT05831007
Vancouver
Anonymous. An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX102-C01 in Patients With Neovascular Age-Related Macular Degeneration (nAMD). Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. 2021.
BibTeX
@misc{anon2021AnOpen,
title = {An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX102-C01 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)},
author = {Anonymous},
journal = {Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine},
year = {2021},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
EyebioKorea, Inc. 2024
Open access · US-GOV
A Randomization, Double-blind, Parallel, Multicenter-Phase 2a Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
Jecho Biopharmaceuticals Co., Ltd. 2022
Open access · US-GOV
A Randomized, Double-masked, Multicenter, Parallel Group, Phase 3 Clinical Trial to Compare the Efficacy and Safety of JL14002 Monoclonal Antibody Injection Versus Ranibizumab Injection in Patients With Neovascular (Wet) Age-Related Macular Degeneration (wAMD)
Graybug Vision 2017
Open access · US-GOV
A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration
Shanghai Refreshgene Technology Co., Ltd. 2023
Open access · US-GOV
A Phase I/IIa, Dose-escalation and Dose-extension Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration
Benobio Co., Ltd. 2025
Open access · US-GOV
A Phase 1, Open Label, Ascending Dose Study to Evaluate the Safety of BBC1501 Administered by Intravitreal Injection for Neovascular Age-Related Macular Degeneration (nAMD)
Chengdu Kanghong Biotech Co., Ltd. 2018
Open access · US-GOV